Pharma Faces / Marina Vasiliou, Biogen Canada
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
AMERICAS
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Pharma Faces / Jorge Rodríguez, PACIV, Puerto Rico
Over the last 22 years, Jorge Rodríguez has grown Puerto Rican industrial automation solutions provider PACIV from…
2020 Trends / A More Measured Tone at the J.P. Morgan Healthcare Conference
David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference 2020 in San Francisco, noting a…
Logistics / Puerto Rican Logistics: Through the Hurricane
Puerto Rico’s export-driven economy could not exist without someone moving, literally, things from point A to…
FDA Drugs Approved in 2019
In 2019, the US FDA’s Center for Drug Evaluation and Research approved 42 novel drugs, down from 59 drugs…
Investment / US Pharma Rewards its Shareholders
In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma…
Opinion / Want to Change Healthcare? Coalitions are Key
Carla Smith looks at the three vital components behind successful strategic alliances in US…
Top 20 Pharma Companies in Puerto Rico
The top 20 pharmaceutical companies in Puerto Rico in the year leading up to December 2017 ranked by sales, with…
In Conversation
Interview: Tania Mori Lucero – Executive Director, National Institute of Public Research, Ecuador
Tania Mori Lucero, executive director of the Ecuadorian National Institute of Public Research (INSPI), details the entity’s role in supporting the elaboration of public health policies under the Ministry of Public Health’s umbrella. Mori highlights the important progress that has been made in the country’s research ecosystem and documents the lack of private-public research collaboration in Ecuador. Ms. Mori, you…
Latest Reports
Focus on Canada
Global Pharma has Reinvented R&D: Will Canadian…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands…
A New Approach to Rare Diseases in Canada
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a…
Read more from Canada >>
Focus on USA
US Pharma Rewards its Shareholders
In 2019 big pharma companies prioritised shareholder payouts and dividends, with…
A More Measured Tone at J.P. Morgan Healthcare Conference…
David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference…
Read more from USA >>
Focus on Puerto Rico
New Puerto Rico Pharma Report January 2020 Out Now
Puerto Rico had to rebuild itself – in many cases quite literally – after…
Company Spotlight: Puerto Rico’s Quality &…
When life sciences companies decide to transfer the production of new drug to…
Read more from Puerto Rico >>
Focus on Brazil
Novartis Teams Up to Tackle Neglected Diseases in Brazil
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation…
Pharma Leadership Strategies for Brazil
Three seasoned pharma executives with a wealth of experience working in Brazil…
Read more from Brazil >>
Focus on Mexico
Mexico: Despite Hurdles, Pharma Market Remains Attractive
The United States Trade Representative Office has been engaging with a number of…
The Ideal Pharma Country Manager: Mexico (Korn Ferry)
What traits, competencies and drivers do you need to be a successful pharma…
Read more from Mexico >>
Focus on Colombia
Colombia: The Great Indian Investment Wave
With the onset of universal public healthcare, new types of foreign actors have…
Colombia: Ramping up the Local Footprint
With Latin America’s best healthcare system in terms of both coverage and…
Read more from Colombia >>
Legal Q&As
Preclinical & Clinical Trial Requirements: Peru
Want to know about preclinical and clinical trial requirements in Peru? Read on! Prepared in association with…
Traditional Medicines and OTC Products: Nicaragua
An insight into traditional medicines and OTC products in Nicaragua. Prepared in association with Bendaña &…
Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs: Mexico
Cannabinoid drugs, medicinal cannabis and opioid drugs in Mexico – a comprehensive legal overview. Prepared in…
The Impact of Government Investment in Health Infrastructure in Ecuador
According to the World Bank, Ecuador had a GDP per capita of USD 5,970 in 2014; a comparable level to USD 6,000 in…
The Ideal Pharma Country Manager: Mexico (Korn Ferry)
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s…
Investment / US Pharma Rewards its Shareholders
In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma…
“Canada Needs to do Better in Supporting Innovative Biopharma”
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in…
Brazilian Pharma: An Industry on a High
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare…
Comprehensive Access to Medicines should be the Priority for National Pharmacare…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…